Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth

The biological evaluation of imidazopiperidines as FAS II inhibitors of Mycobacterium tuberculosis growth has been carried out with a view to assessment of potential as lead compounds for the development of a new TB drug. A summary of the hit evaluation and current challenges is described herein.

Graphical abstractThe biological evaluation of non-covalent FAS II inhibitors containing the imidazopiperidine scaffold against Mycobacterium tuberculosis has been carried out with a view to assessment as a potential lead series of compounds. A summary of the chemistry carried out and the evaluation of results is described herein.Figure optionsDownload full-size imageDownload as PowerPoint slide